Injectable formulations held an estimated 83% share of the GLP-1 market in 2025, a dominance that might seem surprising given how much attention oral versions of these drugs have received in the past two years. The gap between the headlines and the prescribing data captures something important about this market: convenience is not the only variable driving formulation choice, and the arrival of oral options has changed the conversation without yet reshaping the prescription pad at the scale many expected.
Sizing Up a Fast-Diverging Market
The numbers on each side of this formulation split are striking. The oral GLP-1 segment is projected to expand from roughly USD 9.19 billion in 2026 to USD 137.36 billion by 2035, an annualised growth rate which surpasses almost every other category in pharmaceutical manufacturing. Following the FDA approval of a second major oral GLP-1 formulation in April 2026, oral uptake is now projected to grow roughly three times faster than injectables through 2030. Yet even against that backdrop, industry analysts still expect injectable GLP-1s to keep the larger absolute share of prescriptions for the foreseeable future, because the growth-rate differential starts from a much smaller oral base.
Overall demand for the drug class keeps climbing regardless of formulation. GLP-1 prescriptions per 100,000 U.S. adults rose from about 1,884 in the second quarter of 2021 to 8,819 by the first quarter of 2026, and roughly 12.4% of U.S. adults now report taking a GLP-1 medication for weight loss as of mid-2026. That expanding base of patients, many of them newly considering these drugs for weight management rather than diabetes control, is the population in which the injectable-versus-oral decision is now being made most frequently.
Where Competitive Intelligence Fits Into the GLP-1 Market
For pharmaceutical companies, healthcare providers and investors, the discussion about injectables versus oral medications also serves as a question of competitive intelligence. It is not sufficient merely to keep an eye on which products have obtained regulatory approval. The companies have to grasp how their competitors are positioning each formulation, which patient groups they are aiming at, how prescribers are reacting, where payer coverage is changing and how factors such as pricing, manufacturing capacity and distribution might affect market share. By bringing all these different pieces of information together, competitive intelligence can help decision-makers to identify where the market might be heading before such changes become apparent in the published sales figures.
This is especially important in a market where competitive advantage may come from more than clinical efficacy. A competitor could gain ground by securing better payer agreements, building greater manufacturing capacity, offering easier administration, improving telehealth distribution, or targeting specific patient groups with its messaging. Competitive intelligence can help companies compare these strategies, identify gaps in rivals’ plans, and test assumptions about how oral and injectable GLP-1 products will compete as the market evolves. For firms involved in or operating around the GLP-1 market, monitoring these commercial signals alongside clinical data can clarify emerging opportunities and threats.
Why Injectables Still Dominate Prescribing
Pharmacokinetics and Dosing Frequency
The clinical case for injectable formulations rests heavily on pharmacokinetics. Once-weekly injectable GLP-1s achieve steady, sustained receptor engagement because of their extended half-life and subcutaneous depot absorption profile, which smooths out peak-and-trough blood concentration swings compared to oral dosing. That sustained exposure is part of why injectable formulations have shown strong bioavailability and rapid onset of therapeutic effect, and the reduced injection frequency, once a week rather than daily, has itself become an adherence advantage rather than an obstacle, once patients move past initial needle hesitancy.
Manufacturing and Supply Chain Maturity
Injectable GLP-1 manufacturing has also had a multi-year head start. Production lines, cold-chain logistics, and prefilled pen delivery systems have been refined since the first approvals for diabetes indications years before the weight-loss boom, giving injectable manufacturers a scale and reliability advantage that oral formulations, many of which use novel absorption-enhancing technology to survive the gut environment, are still working to replicate at comparable volume.
Why Oral Formulations Are Gaining Ground Anyway
The Needle-Aversion Factor
Patient preference research consistently identifies needle aversion as a meaningful barrier to initiating and continuing injectable therapy. Oral formulations remove that barrier entirely, which analysts cite as a central reason oral uptake is forecast to outpace injectable growth rates, even from a smaller base. For patients who are candidates for GLP-1 therapy but have avoided starting due to injection anxiety, an oral option can be the difference between initiating treatment and not.
Absorption Technology Advances
The technical challenge with oral GLP-1s has long been that digestive enzymes break down peptide molecules before they can be absorbed at meaningful concentrations. Newer oral formulations pair the active peptide with absorption enhancers designed to protect it through the stomach and improve uptake in the small intestine. This workaround has taken years of formulation science to reach a commercially viable, consistent dose. The April 2026 approval of a second major oral formulation is widely read as validation that this absorption technology has cleared a reliability threshold that earlier oral attempts had not.
Dietary and Administration Constraints
Oral GLP-1s are not friction-free, however. Most require administration on an empty stomach with a limited water intake and a waiting period before eating or taking other medications, a routine that some patients find harder to integrate within daily life than a once-weekly injection they can schedule around a convenient day. This administration constraint is one reason some clinicians frame the oral-versus-injectable choice less as a strict upgrade path and more as a genuine trade-off between two different sets of behavioural demands.
Adherence Data: The Deciding Factor for Many Patients
Adherence, not headline convenience, is increasingly treated as the real deciding variable in formulation choice. Long-acting injectable formulations reduce injection frequency, which has been shown to improve adherence by removing daily decision points. In contrast, oral formulations trade that advantage for the removal of needle-related psychological barriers. Neither modality has a clean adherence win across all patient populations, and post-market data collected as oral prescribing volume grows through the back half of 2026 is expected to be the dataset that finally settles which factor dominates in practice, rather than in survey responses about stated preference.
Cost, Access, and Real-World Evidence
Cost and insurance coverage add a layer to the formulation decision that rarely shows up in the clinical literature but matters enormously in practice. Injectable GLP-1s have a longer track record with payers, and many insurance formularies have established prior authorization pathways for injectable products that oral formulations, as newer entrants, have not yet uniformly secured. That coverage gap can make an oral option a patient might otherwise prefer functionally more difficult to access if it carries a materially higher out-of-pocket cost. This dynamic has slowed real-world oral adoption even when head-to-head efficacy looks comparable on paper.
Real-world evidence is also beginning to diverge from the picture painted by registration trials, which typically enrol a narrower and more closely monitored patient population than the general prescribing base. Post-market prescribing data collected as both formulation types scale among broader, more demographically varied populations is expected to reveal adherence and persistence patterns that differ from what randomised trials showed, particularly once patients outside the closely managed conditions of a clinical trial are responsible for their own daily or weekly dosing routine without the same level of structured follow-up.
Patient data
Patient-reported outcome data adds a further wrinkle to the comparison. Surveys of patients who have used both formulation types, either sequentially or through a formulation switch prompted by side effects or access changes, consistently identify gastrointestinal tolerability as a shared concern across both oral and injectable products, suggesting that formulation choice does not significantly change one of the most commonly cited reasons patients discontinue GLP-1 therapy altogether. This observation has pushed some researchers to argue that the oral-versus-injectable debate, while commercially significant, may be less clinically decisive than tolerability management strategies that apply regardless of which formulation a patient starts on.
Customer preference research conducted alongside the oral formulation rollout has also picked up a generational split worth noting. Younger patients newer to chronic medication use more frequently cite pill-based routines as easier to fit into an existing daily supplement or medication stack. In contrast, patients who came to GLP-1 therapy through a diabetes diagnosis and already had experience with injectable insulin or other injectable therapies report less hesitancy regarding continuing an injectable weight-loss product. That split suggests the formulation market may continue to segment more by prior medication experience than by stated convenience preference, complicating simple narratives about oral formulations universally winning over new patients.
How Formulation Choice Plays Out in Telehealth Delivery
Telehealth-delivered GLP-1 care has had to build clinical processes that can support both formulation types without defaulting patients toward whichever is easier to fulfil logistically. A structured example is the TrimRx weight loss program, where physician-supervised intake assesses a patient’s clinical profile, prior injection experience, and administration preferences before a prescribing decision is made, and prescription management continues under medical oversight regardless of which formulation is selected. This intake-driven approach reflects a broader shift in telehealth weight-loss care, where formulation selection is treated as a clinical and behavioural fit question rather than a default determined purely by manufacturer supply.
What Comes Next as the Market Matures
Several forces are likely to keep reshaping this split over the next few years. Continued manufacturing scale-up for oral formulations should gradually narrow the cost and availability gap that has kept injectables dominant. In contrast, additional oral products in the pipeline behind the two currently approved major formulations will increase pricing pressure. At the same time, injectable manufacturers are pursuing even less frequent dosing schedules. If this development reaches the market, it would blunt one of the oral category’s core selling points. Insurance formulary decisions, which have customarily favoured whichever formulation delivers better negotiated rebates rather than pure clinical preference, will likely remain an underappreciated but decisive factor in how quickly the balance actually shifts.
The wider digital health and virtual care ecosystem delivering these medications is itself expanding fast enough to absorb either outcome. The digital health market focused on obesity care alone is valued near USD 5.2 billion in 2026. It is projected to grow at roughly a 15.2% compound annual rate through 2036, growth that will keep pulling new patients into the injectable-versus-oral decision regardless of which formulation ultimately wins more share.
Conclusion
The injectable-versus-oral debate is less a story of one formulation displacing the other and more a story of two delivery systems settling into different, durable niches within a rapidly growing market. Injectable GLP-1s retain a pharmacokinetic and manufacturing head start that keeps them the default for a large share of prescribers, while oral formulations are carving out real and fast-growing demand among patients for whom needle aversion or administration flexibility outweighs the trade-offs of empty-stomach dosing. As both categories mature and supply constraints ease, the formulation conversation is likely to shift from a manufacturing and access question to a genuinely individualised clinical one.
About Octopus Intelligence, the UK and Dubai-based Competitive Insights Consultancy
Octopus is a global competitive insights consultancy with offices in the UK and Dubai.
Our Dubai team works with businesses competing across the Gulf and those looking to enter the region successfully. We combine deep human intelligence with rigorous secondary research to give MENA clients a clear picture of their competitive landscape. Who is moving, how, and why.
We work with MENA and UAE-based businesses across technology, healthcare, financial services, manufacturing, and private equity. Our work covers competitor profiling, market mapping, strategic early warning, and deal-level intelligence for investors and acquirers.
Outsmart your competition. Make the unknown known. Octopus helps you gain clarity in complex markets. With clients and tentacles around the MENA, we deliver sharp, actionable competitive insights through a blend of deep primary (talking to people) and secondary research. If you’re looking to make smarter decisions, beat the competition, and reduce uncertainty, we’re the partner you want on your side.
If you compete in the Gulf and want sharper answers, contact our Dubai team below:
mohamed@octopusintelligence.com | Executive Director – MENA | +971 56 535 3198 | Dubai Digital Park, Dubai Silicon Oasis, Dubai, United Arab Emirates
